Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7121661 and RO7247669 versus nivolumab in advanced or metastatic esophageal squamous cell carcinoma
2024-511403-41-00Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing RO7121661, RO7247669 and nivolumab (3 arms). Primary endpoint: Overall survival. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2024-511403-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511403-41-00.